Perrigo Company plc (NYSE:PRGO) Shares Sold by KBC Group NV

KBC Group NV cut its stake in shares of Perrigo Company plc (NYSE:PRGO) by 94.4% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 6,260 shares of the company’s stock after selling 105,572 shares during the period. KBC Group NV’s holdings in Perrigo were worth $176,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PRGO. Bank of New York Mellon Corp lifted its position in Perrigo by 5.7% during the 4th quarter. Bank of New York Mellon Corp now owns 1,028,172 shares of the company’s stock worth $26,434,000 after acquiring an additional 55,155 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Perrigo by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,048,005 shares of the company’s stock worth $26,944,000 after acquiring an additional 13,835 shares in the last quarter. M&T Bank Corp acquired a new position in Perrigo during the 4th quarter worth approximately $240,000. Raymond James Financial Inc. acquired a new position in Perrigo during the 4th quarter worth approximately $3,177,000. Finally, Edgestream Partners L.P. lifted its position in Perrigo by 95.4% during the 4th quarter. Edgestream Partners L.P. now owns 155,164 shares of the company’s stock worth $3,989,000 after acquiring an additional 75,766 shares in the last quarter. 95.91% of the stock is owned by institutional investors and hedge funds.

Perrigo Price Performance

Shares of PRGO opened at $27.20 on Monday. The company has a market cap of $3.74 billion, a P/E ratio of -20.76 and a beta of 0.45. The stock has a fifty day moving average price of $26.54 and a 200 day moving average price of $26.03. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.36 and a quick ratio of 1.28. Perrigo Company plc has a 12 month low of $23.14 and a 12 month high of $30.93.

Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.04. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.09 billion. Perrigo had a positive return on equity of 8.93% and a negative net margin of 4.16%. The firm’s revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.29 EPS. On average, research analysts forecast that Perrigo Company plc will post 2.56 earnings per share for the current year.

Perrigo Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 17th. Stockholders of record on Friday, May 30th were paid a $0.29 dividend. The ex-dividend date of this dividend was Friday, May 30th. This represents a $1.16 annualized dividend and a dividend yield of 4.26%. Perrigo’s payout ratio is -88.55%.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised Perrigo from a “hold” rating to a “buy” rating in a research report on Saturday. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Perrigo currently has a consensus rating of “Hold” and an average price target of $33.00.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.